Dermatology
Importance of Dermatologic Care for Patients with Cancer
Mario E. Lacouture, MD
I first became interested in treating skin issues associated with cancer about 10 years ago, during my dermatology residency training at the University of Chicago. Many of the agents under clinical development at the time, such as cetuximab (Erbitux) or sorafenib (Nexavar), were causing dose-limitin...
How to Recognize and Manage Vandetanib-induced Photosensitivity
Mario E. Lacouture, MD
Vandetanib (Caprelsa) is an inhibitor of vascular endothelial growth factor receptor, epidermal growth factor receptor, and rearranged during transfection (RET) tyrosine kinase receptors. It has been approved by regulatory agencies for the treatment of unresectable or metastatic medullary thyroid ca...
Prevention and Treatment of Multikinase Inhibitor–induced Hand-Foot Syndrome
Mario E. Lacouture, MD
Multikinase inhibitors (sorafenib [Nexavar], sunitinib [Sutent], pazopanib [Votrient], axitinib [Inlyta], regorafenib [Stivarga]) block various proteins including vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR). They have been approved by regul...
Prevention and Treatment of Acneiform Rash Caused by EGFR Inhibitors
Mario E. Lacouture, MD
Dermatologic Events in Oncology is guest edited by Mario E. Lacouture, MD, an Associate Member in the Division of Dermatology, Department of Medicine, at Memorial Sloan-Kettering Cancer Center, New York. He is a board-certified dermatologist with a special interest in dermatologic conditions that re...
How to Recognize and Manage Hand-Foot Syndrome Due to Capecitabine or Doxorubicin
Beth McLellan, MD
Dermatologic Events in Oncology is guest edited by Mario E. Lacouture, MD, an Associate Member in the Division of Dermatology, Department of Medicine, at Memorial Sloan-Kettering Cancer Center, New York. He is a board-certified dermatologist with a special interest in dermatologic conditions that re...
Melanomas Induced by BRAF Inhibitors
Ashfaq A. Marghoob, MD, and Sarah Yagerman, BS
Dermatologic Events in Oncology is guest edited by Mario E. Lacouture, MD, an Associate Member in the Division of Dermatology, Department of Medicine, at Memorial Sloan-Kettering Cancer Center, New York. He is a board-certified dermatologist with a special interest in dermatologic conditions that re...
Diagnosing and Treating Acute Graft-vs-Host Disease
Jonathan A. Cotliar, MD
Dermatologic Events in Oncology is guest edited by Mario E. Lacouture, MD, an Associate Member in the Division of Dermatology, Department of Medicine, at Memorial Sloan-Kettering Cancer Center, New York. He is a board-certified dermatologist with a special interest in dermatologic conditions that r...
How to Recognize and Manage Ipilimumab-Induced Dermatologic Adverse Events
Jennifer Nam Choi, MD
Ipilimumab (Yervoy) is a fully humanized immunoglobulin (Ig)G1 monoclonal antibody that binds to and inhibits cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4). It acts as a T-cell potentiator, leading to increases in T-cell activation and interleukin-2 secretion. Ipilimumab is U.S. Food and Drug...
How to Measure the Impact of Dermatologic and Mucosal Adverse Events on Symptom Burden and Quality of Life
Christine B. Boers-Doets, RN, MSc
Targeted anticancer therapies like epidermal growth factor receptor (EGFR) inhibitors, multitargeted tyrosine kinase inhibitors (mTKIs), and mammalian target of rapamycin (mTOR) inhibitors frequently result in dermatologic adverse events and mucosal adverse events, or, taken together, mucocutaneous ...
Diagnosing and Treating Chronic Mucocutaneous Graft-vs-Host Disease
Jonathan A. Cotliar, MD
Chronic graft-vs-host disease is a major cause of late, nonrelapse death following allogeneic hematopoietic stem cell transplantation. In addition, chronic graft-vs-host disease results in significant functional impairment and decreased quality of life for long-term survivors of stem cell transplant...
Accidental Extravasation of Chemotherapy
Seppo W. Langer, MD PhD
Accidental extravasation of chemotherapy is a rare but feared complication of cancer treatment. Risk factors for extravasation include medication-related factors (such as the vesicant properties of the compound, or the volume, concentration, and duration of the infusion), patient-related factors (su...
How to Recognize and Manage Intertriginous Eruptions Related to Doxorubicin
Lida Zheng, BS, and Milan J. Anadkat, MD
Intertriginous areas refer to skin folds (such as axillae, inguinal creases, and inframammary creases), which are characterized by increased friction, temperature, and occlusion. Intertriginous drug reactions are an underrecognized side effect associated with pegylated liposomal doxorubicin therapy,...
Life-Threatening Dermatologic Toxicity
Sigrid Barklund, BA, MS, and Milan J. Anadkat, MD
A variety of life-threatening dermatologic adverse events may occur in association with cancer drug therapies. Here, we discuss the recognition and management of three types of such toxicities: type I hypersensitivity/anaphylaxis, Stevens-Johnson syndrome/toxic epidermal necrolysis, and drug rash wi...
